EGFR and lung cancer: In this case, drug response may depend not only on biomarker detection, and the biomarker may not be valid in all contexts (reduced biomarker specificity): as an example, K-ras is valid as biomarker in colon cancer but not in lung cancer for the detection of an inactive EGFR pathway in treatment with EGFR inhibitors.